Yposkesi signs with Servier to manufacture allogenic CAR-T

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Juan Gaertner/Science photo library)
(Image: Getty/Juan Gaertner/Science photo library)

Related tags: Manufacturing, CAR-T, T cell, T cell receptor, T cells, Viral vector, hematological

Servier to work with Yposeski for the production of lentiviral vectors, as the former works to develop allogenic CAR-T cell technology for hematological therapies.

Yposkesi, a gene therapy contract development and manufacturing organization (CDMO), will provide good manufacturing practice (GMP) production of lentiviral vectors to Sevier as the company continues to develop allogenic chimeric antigen receptor (CAR) T-cell technology for hematological malignancies.

According to Servier, cell-based gene therapies that have been obtained with autologous CAR-engineered products have demonstrated positive results in treating hematological malignancies.

Allogenic CAR-T therapies, which will be developed per this agreement, hold the potential to be manufactured in large batches, creating off-the-shelf treatments for a larger number of patients, as opposed to autologous treatments which are created individually from patient’s cells.

Pierre Venesque, EVP of industry at Servier, said in a statement, “Allogenic CAR-T cell therapy is a promising new technology with an amazing potential to treat cancer patients.”

Per the agreement, Servier will have access to Yposkesi’s technology for lentiviral vector manufacturing, which has been used in several clinical trial programs in the EU and US, as well as analytical development, quality assessment resources and capacity.

Servier said it will be focusing 50% of its R&D budget on oncology over the next two years, with a focus on therapies aiming to restore programmed cell death in cancer cells. The company currently has five treatments on the market and is developing 12 therapeutic options.

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more